Written by: Madhu Nag, PhD, Chief Scientific Officer at InSphero
The Seismic Shift from Alternative to Default
The center of gravity in drug development is shifting from animal-first to human-relevant by design. The landscape of preclinical therapeutic development is undergoing a fundamental transformation, driven by an unprecedented, coordinated regulatory and financial push from the United States government. The convergence of recent legislation, strategic regulatory roadmaps, and historic federal funding signals a non-negotiable shift toward human-centric testing and the imminent end of the era of mandatory animal experimentation.
The FDA Modernization Act 2.0 provided critical legal authorization for utilizing non-animal methods. However, the most significant recent development is the National Institutes of Health (NIH)’s launch of the $87 million Standardized Organoid Modeling (SOM) Center. This investment addresses what has been the primary hurdle to the adoption of New Approach Methodologies (NAMs) across the board: the lack of standardized, reproducible protocols across different laboratories. For the biopharma industry, the focus is immediately shifting from proving the validity of NAMs to implementing standardized NAM platforms capable of delivering regulatory-ready data on an industrial scale. This transition structurally validates the use of robust, high-throughput 3D microtissues - including spheroids and organoids - as the essential technology for achieving newly prioritized goals of scientific reproducibility and regulatory acceptance.
The Regulatory Imperative - Legislation and Policy in Lockstep
The Legal Foundation: From Animal Mandate to Nonclinical Default
For nearly a century, drug development in the U.S. was dictated by the Federal Food, Drug, and Cosmetics Act of 1938, which mandated animal testing for every new drug protocol. This centuries-old requirement, originally intended to ensure safety, has been structurally refuted by recent advancements in science and subsequent legislation.
The landmark legislative step was the passage of the FDA Modernization Act 2.0 (FDAMA 2.0) in late 2022. This act provided the necessary legal pathway, authorizing the use of non-animal alternatives for Investigational New Drug (IND) applications. Crucially, FDAMA 2.0 did not ban animal testing but transformed it from a mandatory requirement into a permissible option, effectively establishing NAMs as a legally viable alternative for demonstrating safety and efficacy.
Timeline of Key Milestones Driving the Rise of Non-Animal In Vitro Testing
Further legislative momentum is evidenced by the proposed FDA Modernization Act 3.0 (FDAMA 3.0). This bipartisan effort aims to finalize the systemic change by mandating that the FDA replace all regulatory references to "animal tests," "animal data," and "animal models" with the scientifically broader terms of "nonclinical tests," "nonclinical data," and "nonclinical models" throughout its regulations governing IND applications. This progression - moving from legislative permission (FDAMA 2.0) to mandated language change (FDAMA 3.0) - demonstrates an institutional commitment to embedding NAMs permanently into the regulatory structure. This coordinated political and legislative drive ensures that the regulatory landscape is permanently moving away from animal-centric paradigms, making long-term infrastructure investment in scalable NAMs a necessity for pharmaceutical sponsors.
The FDA Roadmap: Phased Transition and Strategic Targets
The FDA’s shift is primarily driven by the poor predictive accuracy of traditional animal models. Statistics show that over 90% of drugs appearing safe and effective in animals ultimately fail in human clinical trials, often due to unanticipated safety or efficacy issues. This failure highlights the profound scientific limitations of interspecies extrapolation and reinforces the superior relevance of human-based models.
To manage this transition, the FDA published its "Roadmap to Reducing Reliance on Animal Testing in Preclinical Safety Studies."
The roadmap identifies Monoclonal Antibodies (mAbs) as an immediate focus area and a strategic "regulatory bridgehead" for NAM adoption. Current FDA requirements for mAbs mandate extensive, costly, and lengthy repeat-dose toxicity studies in animals, often requiring up to 144 non-human primates (NHPs) over periods of one to six months. This process is inefficient, costing up to $750 million and taking up to nine years per therapeutic. Furthermore, animal immunogenicity to human mAbs is poorly predictive of human outcomes due to fundamental interspecies immune system differences, exemplified tragically by cases like the TGN1412 monoclonal antibody, which caused a life-threatening cytokine storm in humans despite appearing safe in monkey studies.
NAMs offer a superior solution. For mAb safety, human-relevant models - such as in vitro human liver chips integrated with immune cells - can specifically evaluate target-specific and off-target effects and detect cytokine release syndrome far better than non-human systems.
The implementation strategy detailed in the roadmap encourages sponsors to submit NAM data - such as organoid or in silico results - in parallel with traditional packages (as supportive data). Critically, the FDA is also seeking pilot cases where sponsors, based on a strong scientific rationale (e.g., a mAb targeting a human-specific receptor), can propose to entirely waive the animal study requirement. The successful use of human 3D immune-competent liver models to predict cytokine release syndrome immediately provides a high-return-on-investment use case, establishing strong precedents for the adoption of advanced 3D systems. The FDA’s stated long-term goal (3–5 years) is to make animal studies the exception rather than the norm.
Internal Alignment and Qualification: The FDA’s Engine Room
The FDA is systematically structuring its internal capabilities to facilitate this transition. The agency has committed $5 million in new funding to support its New Alternative Methods Program (NAMP), centralizing coordination and management across all FDA centers.
Two key working groups are driving the scientific integration:
- The Alternative Methods Working Group (AMWG): This group focuses on processes to formally qualify in vitro alternative methods for regulatory use, providing clear guidelines to external stakeholders, and conducting applied research to advance policy development.
- The Modeling and Simulation Working Group (M&S WG): This group concentrates on computational tools, including AI, Machine Learning (ML), and Physiologically Based Pharmacokinetic (PBPK) modeling. The M&S WG is tasked with raising awareness, promoting consistent review, and serving as a scientific resource for these in silico technologies, which can inform first-in-human dosing and justify waving certain animal studies.
The FDA’s dual focus on AMWG (validating the in vitro component) and the M&S WG (integrating the in-silico component) confirms that the future of preclinical safety is the Integrated Testing Strategy (ITS). For computational models -AI/ML algorithms, Quantitative Systems Pharmacology (QSP), and PBPK modeling - to be accepted by the M&S WG and utilized for regulatory decisions, they require vast quantities of standardized, high-quality, human-relevant data.
Scalable 3D microtissue platforms are, therefore, the foundational data engine for realizing the full promise of AI-driven drug development.
